ATR and cancer: Notably, compared to OSU, MEC-1 expressed lower levels of SLC7A11/xCT (Figure 1A,B) suggesting a potential sensitivity to PRIMA1Met treatment; indeed, it has been demonstrated that the expression of SLC7A11 may represent a superior determinant of response to PRIMA-1Met compare to the mutational status of p53 alone in cancer cells [24].